↓ Skip to main content

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study

Overview of attention for article published in Frontiers in immunology, April 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study
Published in
Frontiers in immunology, April 2023
DOI 10.3389/fimmu.2023.1142256
Pubmed ID
Authors

Jusheng An, Xiumin Li, Jing Wang, Lijing Zhu, Ruifang An, Kui Jiang, Yi Huang, Ke Wang, Guiling Li, Chunyan Wang, Jianlin Yuan, Xiaoli Hou, Guiyu Yang, Jing Li, Qingyu Wang, Jun Zhu, Lingying Wu

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 20%
Librarian 1 10%
Unknown 7 70%
Readers by discipline Count As %
Medicine and Dentistry 2 20%
Business, Management and Accounting 1 10%
Unknown 7 70%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2023.
All research outputs
#17,579,839
of 25,727,480 outputs
Outputs from Frontiers in immunology
#20,721
of 32,179 outputs
Outputs of similar age
#244,691
of 414,753 outputs
Outputs of similar age from Frontiers in immunology
#820
of 1,426 outputs
Altmetric has tracked 25,727,480 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 32,179 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 414,753 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,426 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.